Physician profile
Doo Whan Cho
NPI 1609891662
$9,032.12
in general payments reported to CMS, 2019-2025
24 companies · $2,433 in 2025
The $2,433 reported for 2025 was more than what a typical Neurodevelopmental Disabilities (Psychiatry & Neurology) provider received nationally (typical 2025 total: $328).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $455 · 2021: $1,085 · 2022: $1,266 · 2023: $1,615 · 2024: $1,552 · 2025: $2,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,588 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,587.76 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,494.20 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,124.35 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $971.88 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $869.70 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $854.88 | 2020-2025 | Caplyta |
| Alkermes, INC. | $577.79 | 2020-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $501.44 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $386.78 | 2019-2025 | Trintellix |
| Allergan, INC. | $344.98 | 2019-2020 | |
| Axsome Therapeutics, INC. | $325.81 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $322.55 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $288.81 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $191.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $150.49 | 2022-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $130.20 | 2019-2023 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $129.53 | 2022-2025 | Qelbree |
| Corium, LLC | $102.70 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $76.99 | 2020-2025 | Fanapt |
| Noven Therapeutics, LLC | $64.63 | 2024 | Xelstrym, Secuado |
| Eisai INC. | $33.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.93 | 2023 | Quviviq |
| Shire North American Group INC | $24.42 | 2019 | |
| Indivior INC. | $21.68 | 2025 | Sublocade |
| Neos Therapeutics, Lp | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doo Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.